Analysis of Vision Loss Caused by Radiation-Induced Optic Neuropathy After Particle Therapy for Head-and-Neck and Skull-Base Tumors Adjacent to Optic Nerves

Demizu, Yusuke; Murakami, Masao; Miyawaki, Daisuke; Niwa, Yasue; Akagi, Takashi; Sasaki, Ryohei; Terashima, Kazuki; Suga, Daisaku; Kamae, Isao; Hishikawa, Yoshio

doi:10.1016/j.ijrobp.2008.12.068

Cited by 65 publications

(64 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,6,10,19 Particle therapy, such as carbon ion therapy (CIT) and proton therapy (PT), can deliver high-dose radiation to tumours while minimizing the dose delivered to organs at risk because of its precise dose distribution compared with conventional photon therapy. [22][23][24][25][26][27][28][29][30][31][32] Particle beams possess a physical characteristic called the Bragg peak, which emits a relatively low dose near the body surface and releases the maximum energy just before it stops in the depth. Recently, several investigators have reported on the efficacy of CIT for sacral chordomas, describing high LC rates and low toxicities.…”

mentioning

confidence: 99%

Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma

Mima¹,

Demizu²,

Jin³

et al. 2014

BJR

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma

Mima¹,

Demizu²,

Jin³

et al. 2014

BJR

View full text Add to dashboard Cite

show abstract

“…The GTV of the three patients who developed blindness was 39.3 (range=34.9-62.6) cc and was larger than the median GTV 37.9 (range= 7.7-89.2) cc of all patients. Regarding optic neuropathy, which was a major cause of visual impairment, it was reported that a maximum C-ion RT dose of 52 to 57 Gy (RBE) to the optic nerve was a significant negative prognostic factor (22,23). Anatomically, ONB develops from the olfactory epithelium and is in close proximity to the orbit.…”

Section: Discussionmentioning

confidence: 99%

A Retrospective Multicenter Study of Carbon Ion Radiotherapy for Locally Advanced Olfactory Neuroblastomas

Suefuji

Koto

Demizu

et al. 2018

View full text Add to dashboard Cite

Abstract. The purpose was to evaluate efficacy and safety of carbon ion radiotherapy (C-ion RT) in patients with locally advanced olfactory neuroblastomas (ONBs). This study was a sub-analysis of the Japan Carbon-Ion Radiation Oncology Study Group Study (1402 HN, UMIN000024473). Clinical data of T4 ONBs treated with C-ion RT at fourOlfactory neuroblastoma (ONB) of the head and neck is a rare malignant tumour that arises from the olfactory neuroepithelium in the upper nasal cavity with extension into the skull base, into the orbit and to the intracranial space (1, 2). Surgery is considered a curative treatment for localized ONB, while postoperative radiotherapy (RT) is necessary for advanced ONBs. Definitive RT alone is considered insufficient therapy for ONBs (3). In advanced cases, intracranial extension may pose a surgical challenge (4). Surgical resection followed by postoperative RT is associated with reduced local recurrence (5).Although ONB has been traditionally regarded as a radioresistant tumour, RT has widely been used as part of the treatment algorithm in adjuvant and definitive settings.Compared to photons, carbon ions (C-ions) offer a higher linear energy transfer and greater relative biological effectiveness (RBE) and therefore provide a higher probability of tumour control. The physical characteristics of C-ions, such as their Bragg peak and small lateral scattering, are theoretically superior to those of photons in that C-ions can allow a more localized delivery of the radiation dose.This study is the first report for ONBs treated by C-ion RT. C-Ion RT for various head and neck radioresistant malignancies has shown excellent results. Jingu et al. reported clinical results of 37 patients with malignant melanoma of the head and neck who received C-ion RT with concurrent chemotherapy. The 3-year local control (LC) and overall survival (OS) rates were 81.1% and 65.3%, respectively (6). Koto et al. reported 3-year LC and OS rates of 76.9% and 59.1%, respectively, in 22 patients with locally advanced sinonasal adenocarcinoma + reated with C-ion RT (7). Therefore, C-ion RT might be a useful and potentially curative option for unresectable head and neck tumours, including ONBs.In November 2003, following a clinical trial, the Ministry of Health, Labour and Welfare in Japan approved C-ion RT as a highly advanced medical technology. As of the end of 2014, there were four C-ion facilities functioning in Japan

show abstract

“…At time of radiation the patient's age was older than 60 years, which has been depicted as significant covariate for vision loss. The patient did not suffer from diabetes, the second significant covariate for RION [4]. Female gender and arterial hypertension have not been found to be significant risk factors for radiation-induced optic neuropathy [4].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, a pre-existing compression to the optic nerves and the chiasm may predispose these structures to injury by radiotherapy [3]. RION has been described mainly in patients with tumors of nasopharynx, paranasal sinuses, nasal cavity, pituitary adenoma, craniopharyngioma, skull base and orbita [2,4,5]. Since some chemotherapeutic agents, namely vincristine, nitrosoureas and cisplatin [6,7] are associated with optic nerve toxicity and/or can serve as radiosensitizers [8], those patients receiving adjuvant chemotherapy have an especially high risk of developing RION.…”

Section: Introductionmentioning

confidence: 99%

Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report

et al. 2010

View full text Add to dashboard Cite

BackgroundRadiation induced optic neuropathy (RION) is a rare but severe consequence of radiation therapy that is associated with adjuvant chemotherapy, specifically therapy with vincristine or nitrosoureas. However, there is very little evidence regarding the occurrence of RION after concomitant radiochemotherapy with temozolomide.Case PresentationThe case of a 63 year old woman with glioblastoma multiforme and concomitant radiochemotherapy with temozolomide is described. Due to a slight depressive episode the patient also took hypericum perforatum. Five months after cessation of fractionated radiation and adjuvant chemotherapy with temozolomide (cumulative dose of 11040 mg) the patient developed bilateral amaurosis due to RION. Tumor regrowth was excluded by magnetic resonance imaging. After the application of gadolinium a pathognomonic contrast enhancement of both prechiasmatic optic nerves could be observed.ConclusionsIn this patient, the occurrence of RION may have been the result of radiosensitization by temozolomide, which could have been strengthened by hypericin. Consequently, physicians should avoid a concomitant application of hypericum perforatum and radiochemotherapy.

show abstract

Analysis of Vision Loss Caused by Radiation-Induced Optic Neuropathy After Particle Therapy for Head-and-Neck and Skull-Base Tumors Adjacent to Optic Nerves

Cited by 65 publications

References 19 publications

Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma

Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma

A Retrospective Multicenter Study of Carbon Ion Radiotherapy for Locally Advanced Olfactory Neuroblastomas

Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report

Contact Info

Product

Resources

About